Clinical study on the treatment of gastroesophageal reflux disease with Xuanfu Daizhe Decoction and gastric reversal therapy from the perspective of T lymphocyte immune balance

TAN Shupei; WANG Yi; LI Xiwen; YUAN Hongxia; LIU Ju

doi:10.3969/j.issn.1671-038X.2025.06.02

Article navigation > Chin J Integr Tradit West Med Dig > 2025 > 33(6): 577-581

Next Article Previous Article

TAN Shupei, WANG Yi, LI Xiwen, et al. Clinical study on the treatment of gastroesophageal reflux disease with Xuanfu Daizhe Decoction and gastric reversal therapy from the perspective of T lymphocyte immune balance[J]. Chin J Integr Tradit West Med Dig, 2025, 33(6): 577-581, 587. doi: 10.3969/j.issn.1671-038X.2025.06.02

Citation:

Clinical study on the treatment of gastroesophageal reflux disease with Xuanfu Daizhe Decoction and gastric reversal therapy from the perspective of T lymphocyte immune balance

1.
Graduate College, Tianjin University of Traditional Chinese Medicine, Tianjin, 301617, China
2.
Kunshan Hospital of Traditional Chinese Medicine
3.
College of Traditional Chinese Medicine, Tianjin University of Traditional Chinese Medicine

More Information

Corresponding author: LIU Ju, E-mail: liujupopo@126.com

Received Date: 02 December 2024

Publish Date: 15 June 2025

Abstract

Abstract

Objective
To observe the effect of Xuanfu Daizhe Decoction on T lymphocyte immune balance in patients with gastroesophageal reflux disease(GERD).
Methods
A cohort of 72 patients diagnosed with GERD characterized by Qi deficiency was randomly divided into a treatment group and a control group, with 36 participants in each group. The spleen and stomach weakness score and changes in GERD symptoms before and after treatment with Xuanfu Daizhe Decoction were observed, and the expression levels of T lymphocyte subsets and associated cytokines in peripheral blood were detected. At the same time, 30 healthy volunteers were recruited as the healthy control group.
Results
① Spleen and Stomach Weakness Assessment: The total score and individual symptoms of the treatment group were better than those of the control group, except for weak mouth, persistent abdominal pain, and smooth bowel sounds(P < 0.05). ②Rating of the Reflux Disease Questionnaire(RDQ)Assessment: The total scores and individual symptoms of heartburn, acid reflux, and overeating in the treatment group were better than those in the control group(P < 0.05). ③Symptom Evaluation of Deficiency Qi Reversal Syndrome in GERD: The total scores and individual symptoms, except for epigastric pain, were better in the treatment group than those in the control group(P < 0.05); ④Evaluation of the therapeutic effectiveness of Esophageal Mucosal Manifestations via Gastroscopy: The total effective rate of the treatment group was higher than that of the control group(P < 0.05); ⑤The expression of T lymphocyte subsets and related cytokines: Before treatment, the treatment group, control group, and healthy control group showed significant differences in various related indicators(P < 0.05). After treatment, the treatment group and control group showed significant differences in various related indicators compared with pre-treatment(P < 0.05). After treatment, the expression of Th1, Th1/Th2, Th17/Treg, T-bet, IFN-γ and TNF-α was relatively lower in the treatment group compared to the control group, while the expression of Th2, Treg, GATA-3, Foxp3, IL-4, IL-5, TGF-β and IL-10 was relatively higher in the treatment group. The differences between the two groups were statistically significant(P < 0.05).
Conclusion
Xuanfu Daizhe Decoction can restore the disrupted immune homeostasis of T lymphocytes, ameliorate symptoms of GERD with middle deficiency and Qi reversal and reduce the spleen and stomach weakness scores.
- gastroesophageal reflux disease /
- weakness of spleen and stomach /
- T lymphocyte immune balance /
- Xuanfu Daizhe Decoction /
- reduce gastric reflux

FullText(HTML)

References

[1]	张声生, 朱生樑, 王宏伟, 等. 胃食管反流病中医诊疗专家共识意见(2017)[J]. 中国中西医结合消化杂志, 2017, 25(5): 321-326. doi: 10.3969/j.issn.1671-038X.2017.05.01 CrossRef Google Scholar
[2]	El-Serag HB, Sweet S, Winchester CC, et al. Update on the epidemiology of gastro-oesophageal reflux disease: a systematic review[J]. Gut, 2014, 63(6): 871. doi: 10.1136/gutjnl-2012-304269 CrossRef Google Scholar
[3]	Hunt R, Armstrong D, Katelaris P, et al. World Gastroenterology Organisation Global Guidelines: GERD global perspective on gastroesophageal reflux disease[J]. J Clin Gastroenterol, 2017, 51(6): 467-478. doi: 10.1097/MCG.0000000000000854 CrossRef Google Scholar
[4]	刘菊, 苗嘉萌, 李姿, 等. 胃食管反流病患者脾胃虚弱评分与GerdQ的相关性研究[J]. 中国中西医结合消化杂志, 2019, 27(6): 411-414. doi: 10.3969/j.issn.1671-038X.2019.06.03 CrossRef Google Scholar
[5]	袁红霞, 张鹏, 田晶晶. 旋覆代赭汤治疗反流性食管炎研究思路[C]. 中华中医药学会脾胃病分会第二十五届全国脾胃病学术交流会论文汇编. 天津中医药大学, 2013: 2. Google Scholar
[6]	陈旻湖, 侯晓华, 肖英莲, 等. 2014年中国胃食管反流病专家共识意见[J]. 中华消化杂志, 2014, 34(10): 155-168. Google Scholar
[7]	郑莜萸, 任德权, 曹文庄, 等. 中药新药临床研究指导原则[M]. 北京: 中国医药科技出版社, 2002: 361-371. Google Scholar
[8]	Winkelsett L, Malfertheiner P, Wex T, et al. Mucosal two-step pathogenesis in gastroesophageal reflux disease: repeated weakly acidic stimulation and activation of protease-activated receptor-2 on mucosal interleukin-8 secretion[J]. Digestion, 2018, 98(1): 19-25. doi: 10.1159/000486480 CrossRef Google Scholar
[9]	Dunbar KB, Agoston AT, Odze RD, et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes[J]. JAMA, 2016, 315(19): 2104. doi: 10.1001/jama.2016.5657 CrossRef Google Scholar
[10]	Kavanagh ME, Conroy MJ, Clarke NE, et al. Impact of the inflammatory microenvironment on T-cell phenotype in the progression from reflux oesophagitis to Barrett oesophagus and oesophageal adenocarcinoma[J]. Cancer Lett, 2016, 370(1): 117-124. doi: 10.1016/j.canlet.2015.10.019 CrossRef Google Scholar
[11]	杜昕, 袁红霞, 檀金川. 旋覆代赭汤加减治疗反流性食管炎临床研究[J]. 时珍国医国药, 2013, 24(1): 162-164. Google Scholar
[12]	戚经天, 秦宝玥, 刘菊, 等. 袁红霞教授运用食管康加减治疗反流性食管炎经验[J]. 四川中医, 2016, 34(1): 5-6. Google Scholar